Following the previously signed OEM agreement, Hain Lifescience has now placed their first order  of 25 Arrow instruments. The instruments are scheduled to be delivered in Q2-2010.  The total value of this order for NorDiag is NOK 4 - 6 million.

"We are delighted to see the first order come through. Hain Lifescience has already placed two Arrow instruments in South Africa for validation on a large project. We have great expectations to their tuberculosis assay due to its official recommendation from WHO, which expands the market opportunity significantly. Our technologies fits perfect together and we will be able to offer customers an affordable and easy to use test system. This order including future reagent sales is worth NOK 4-6 million over the next 3-5 years", says Mårten Wigstøl, CEO of NorDiag.
 
February 15, 2010; NorDiag ASA and Hain Lifescience GmbH entered into an OEM agreement for the Arrow instrument platform and sample preparation reagents to be used in connection with Hain Lifescience  molecular biological assays.  Hain Lifesciences currently have a range of assays, among others Tuberculosis, H-pylori and C-diff. The tuberculosis assay is officially recommended by World Health Organisation (WHO).

Contact:
CEO Mårten Wigstøl  -  Phone: +47 91165775

 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing  utomated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give faster and more precise answers, and are the fastest growing field within the diagnostics industry. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 34.3 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information - www.nordiag.com.
 
About Hain Lifescience GmbH:
Hain Lifescience GmbH is a private corporation with its headquarters based in Nehren, Germany, subsidiaries in Spain, South Africa, Kenya and operating through an excellent network of distributors in more than 40 countries throughout the world. Hain Lifescience GmbH is focusing on molecular diagnostics in the field of medical microbiology and human genetics. Within the business year of 2009 the Hain Group achieved a total turnover of € 18.1 Mio. in its business with molecular diagnostics and laboratory services.

Read the notice in Norwegian here.